Jul, 15 2022

Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG dominated the Ecuador Acute Myeloid Leukemia Drugs Market in 2021

Ecuador Acute Myeloid Leukemia Drugs Market is expected to grow with the CAGR of 4.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/ecuador-acute-myeloid-leukemia-drugs-market

Ecuador acute myeloid leukemia drugs market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenarios.

Some of the major players dealing in the acute myeloid leukemia market are introducing strong range of product portfolios. This helped companies to maximize sales with enhanced product portfolio.

Pfizer Inc., is dominating player in the Ecuador acute myeloid leukemia drugs market. The other key players existing in the market includes are Bristol-Myers Squibb Company, Novartis AG, AbbVie Inc., Merck Sharpe and Dohme, F. Hoffmann-La Roche Ltd, FRESENIUS KABI AG and Others.

Pfizer Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, U.S. The company focuses on providing quality standards, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. The company offers range of product categories including Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Anti Infectives in which market focused category fall under oncology. The company is taking strategic initiatives by collaboration.

The company has global presence in North America, Europe, Middle East and Africa, Asia-Pacific and South America and Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic) and Pfizer Egypt S.A.E. (Egypt), among others among others are the subsidiary of Merck KGaA.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, U.S. The company focuses on innovating new solutions in oncology, hematology, immunology and cardiovascular disease by accelerating advancing treatments and improving patients’ therapies. The company offers range of product categories Solid tumors, Hematology, Cardiovascular, Immunology, Fibrotic Diseases, Neuroscience, Translational medicine, Digital health, Cell therapy and Research technologies and our market focused category is immunology and hematology. The company is taking strategic initiatives to increase its product portfolio.

In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Peru, thereby increasing the market growth

The company has global presence in North America, Asia Pacific, South America, Europe, and Latin America. The company has many subsidiaries such as BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., among others.

Acute Myeloid Leukemia Drugs Market

Novartis AG

Novartis AG was founded in 1996 and is headquartered in Baden-Württemberg, Switzerland. The company focuses on innovating new solutions for various healthcare challenges. The company offers products in following categories Cancer, Cardiovascular, Renal & Metabolism, Immunology & Dermatology, Ophthalmology, Neuroscience, Respiratory and innovative medicines is the market focused category from which our market focused category is innovative medicines and cancer. The company is taking strategic initiatives to increase its product portfolio.

In September 2017, Novartis Ag, had received approval from the European Union, for Rydapt for treatment of FLT3-mutated acute myeloid leukemia (AML). The approval received would ensure post marketing approval of Rydapt in Europe and in countries in South America. The approval received was based on data from largest landmark trials, in acute myeloid leukemia

The company has global presence in North America, Europe, South America, Middle East and Africa, Asia-Pacific. The company has many subsidiaries such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium), among others.

CHOOSE LICENCE TYPE

Enterprise User 7000
Single User 4800
DBMR Factbook 3000
DBMR Prime 8000
DBMR Supreme 12000

Buy Now Add to Cart

Advance Formative Research Customization Request for bulk Reports

Latest Press Release

Increasing Incidence of Hematopoietic Stem Cell Transplants (HSCT) is expected to drive the Growth of Global Graft-Versus-Host Disease (GvHD) Treatment Market

Growing Demand Of Automatic Water Dispensers In Developing Countries Drives the Growth of the North America, Europe, and the Middle East and Africa Water Dispensers Market

Increasing Prevalence of ENT Disorders is driving the Growth of the Global ENT Devices Market

Increasing Demand for Lightweight Components from the Automotive and Aerospace Industries is driving the growth of North America, Europe and Asia-Pacific Additive Manufacturing Market

Increasing Consumer Awareness Regarding Health Risks Associated with Contaminated Water is Expected to Drive the Growth for the North America, Europe and Middle East and Africa Water Filters Market

VIEW ALL

Client Testimonials

David Manning - Thermo Fisher Scientific

Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Manager - Market Analytics,

Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,

(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Business Intelligence and Analytics,

Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst,

Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director,

Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,

A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director,

Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager,

Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations,

GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst,

Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager,

Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment

MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer

Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro

Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)

UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future

Press Release